- Home
- OPHC vs MNOV Comparison
OPHC vs MNOV Comparison
Compare OPHC & MNOV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | OPHC | MNOV |
|---|---|---|
| Founded | 2000 | 2000 |
| Country | United States | United States |
| Employees | N/A | 6 |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 67.5M | 67.9M |
| IPO Year | 2012 | 2004 |
Fundamental Metrics
Financial Performance| Metric | OPHC | MNOV |
|---|---|---|
| Price | $5.97 | $1.39 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | $6.50 | ★ $7.50 |
| AVG Volume (30 Days) | 37.8K | ★ 72.5K |
| Earning Date | 04-24-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.20 | N/A |
| Revenue | N/A | ★ $2,360,807.00 |
| Revenue This Year | $17,095.98 | N/A |
| Revenue Next Year | N/A | $180.00 |
| P/E Ratio | $29.90 | ★ N/A |
| Revenue Growth | N/A | ★ 194.15 |
| 52 Week Low | $3.91 | $1.17 |
| 52 Week High | $5.98 | $1.96 |
Technical Indicators
Market Signals| Indicator | OPHC | MNOV |
|---|---|---|
| Relative Strength Index (RSI) | 64.13 | 54.63 |
| Support Level | $5.40 | $1.31 |
| Resistance Level | N/A | $1.52 |
| Average True Range (ATR) | 0.14 | 0.06 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 94.74 | 43.54 |
Price Performance
Historical ComparisonAbout OPHC OptimumBank Holdings Inc.
OptimumBank Holdings Inc serves as a bank holding company for OptimumBank. The Bank provides community banking services to individuals and corporate customers. The services provided by the bank include demand interest-bearing and non-interest-bearing accounts, negotiable order of withdrawal accounts, borrowings, repayment of loans, money market deposit accounts, debit cards, automated teller machines, and other bank related services.
About MNOV Medicinova Inc
MediciNova Inc is a biopharmaceutical company developing novel therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus on the United States (U.S.) market. It is currently focused on developing MN-166 (ibudilast) for neurological and other disorders such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and prevention of acute respiratory distress syndrome (ARDS); and MN-001 (tipelukast) for fibrotic and other metabolic disorders such as nonalcoholic fatty liver disease (NAFLD), and hypertriglyceridemia.